ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9700
-0.0500 (-1.66%)
At close: 4:00PM EDT

2.9700 0.00 (0.00%)
After hours: 7:14PM EDT

Stock chart is not supported by your current browser
Previous Close3.0200
Open2.3500
Bid2.9300 x 36200
Ask2.9700 x 45900
Day's Range2.8100 - 3.1800
52 Week Range2.1400 - 18.5000
Volume8,665,150
Avg. Volume5,641,756
Market Cap672.384M
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-2.6230
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.47
Trade prices are not sourced from all markets
  • Opioid Epidemic: Will Pharmas Scramble To Settle As Landmark Case Looms?
    Investor's Business Daily

    Opioid Epidemic: Will Pharmas Scramble To Settle As Landmark Case Looms?

    Endo International and Allergan could avoid going to trial in a landmark case out of Ohio accusing pharmaceutical companies of marketing practices that preceded the opioid epidemic.

  • Endo Up on Settlement of a Few Cases Related to Opioid Drugs
    Zacks

    Endo Up on Settlement of a Few Cases Related to Opioid Drugs

    Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.

  • Are Options Traders Betting on a Big Move in Endo (ENDP) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Endo (ENDP) Stock?

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

  • Why Baidu, Endo International, and Hilton Grand Vacations Jumped Today
    Motley Fool

    Why Baidu, Endo International, and Hilton Grand Vacations Jumped Today

    Despite some nervousness in the broader market, earnings and other good news helped boost these stocks.

  • Why Endo International Shares Are Soaring Again Today
    Motley Fool

    Why Endo International Shares Are Soaring Again Today

    Investors are cheering the drugmaker's settlement in principle of two lawsuits related to its opioid drugs.

  • Reuters

    UPDATE 2-Drugmakers Endo, Allergan agree to $15 mln in settlements in major opioid case

    Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic. The tentative deals disclosed on Tuesday came ahead of the first trial to result from 2,000 lawsuits pending in federal court in Cleveland largely by local governments seeking to hold drug companies responsible for the deadly epidemic. Endo announced said it had reached an agreement-in-principle to pay Cuyahoga and Summit counties $10 million to and provide them up to $1 million worth of two of its of its drug products free of charge.

  • MarketWatch

    Endo's stock soars after settlement agreement on track 1 opioid cases

    Shares of Endo International PLC soared 30% in active morning trading Tuesday, after the generic drug maker said it has reached a "settlement in principle" to resolve "track 1" opioid cases. Trading volume rose to over 7.6 million shares, already more than the full-day average of about 6 million shares. As part of the settlement, Endo will pay $10 million and provide up to $1 million of its Vasostrict and Adrenalin products free of charge. Endo said the settlement includes no admission of wrongdoing, fault or liability, and is based solely on the avoidance of litigation risk and associated costs. Endo said its subsidiaries involved in the settlement include Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical Inc. and Par Pharmaceuticals Companies Inc., while the plaintiffs are the County of Cuyahoga, Ohio and the County of Summit Ohio. "This is a favorable outcome for the Company," said Endo Chief Legal Officer Matthew Maletta. "As context, the cash portion of the settlement approximates the estimated cost to Endo of proceeding through trial while the product portion of the settlement illustrates the importance of Endo's critical care products." The stock has still tumbled 55% year to date, while S&P 500 has gained 16%.

  • CNW Group

    Endo Announces Settlement in Principle to Resolve "Track 1" Opioid Cases

    Endo Announces Settlement in Principle to Resolve "Track 1" Opioid Cases

  • TheStreet.com

    Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit

    Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.

  • TheStreet.com

    [video]Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

    Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

  • Why Mallinckrodt and Endo International Shares Jumped Today
    Motley Fool

    Why Mallinckrodt and Endo International Shares Jumped Today

    Investors appear to have some confidence that the companies will settle their opioid lawsuits.

  • Is Endo International (ENDP) A Great Pick for Value Investors?
    Zacks

    Is Endo International (ENDP) A Great Pick for Value Investors?

    Is Endo International Holdings (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

  • BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2
    Zacks

    BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2

    BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.

  • Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
    Zacks

    Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

    Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

  • Endo International (ENDP) Q2 2019 Earnings Call Transcript
    Motley Fool

    Endo International (ENDP) Q2 2019 Earnings Call Transcript

    ENDP earnings call for the period ending June 30, 2019.

  • Here's Why Endo International Is Falling Today
    Motley Fool

    Here's Why Endo International Is Falling Today

    Shares fall even though the company posted better-than-expected results. What can explain the move?

  • ACCESSWIRE

    Endo International Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2019 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 6, 2019 at 7:30 ...

  • Endo International (ENDP) Q2 Earnings and Revenues Surpass Estimates
    Zacks

    Endo International (ENDP) Q2 Earnings and Revenues Surpass Estimates

    Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Endo Reports Second-Quarter 2019 Financial Results

    - Operating Performance Led by Year-over-Year Double-Digit-Percentage Growth in Revenues of Sterile Injectables Segment and Specialty Products Portfolio of Branded Pharmaceuticals Segment - - Endo Reaffirms ...

  • CNW Group

    Endo Applauds U.S. District Court Decision that Vasopressin Cannot be Used for Compounding by Outsourcing Facilities

    In March 2019 , the FDA determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act.  As a result, it is unlawful for outsourcing facilities to sell compounded vasopressin products unless they manufacture those products using an FDA-approved vasopressin product, rather than bulk vasopressin, or if vasopressin were to be added to the FDA's drug shortage list.  Par Sterile Products, LLC ("Par"), a subsidiary of Endo, is the manufacturer of Vasostrict®, the only vasopressin product approved by the FDA.  Following the FDA's decision, Athenex, Inc.  and two of its affiliates sued the FDA seeking to overturn the vasopressin decision.  Par and another Endo subsidiary intervened as defendants in the action. "At Endo, delivering high quality products and ensuring patient safety are our top priorities and we are very pleased with the district court's decision confirming the FDA's determination that there is no clinical need to bulk compound vasopressin," said Matthew J. Maletta , Executive Vice President and Chief Legal Officer of Endo.

  • PR Newswire

    Endo Appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics

    DUBLIN , Aug. 1, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, ...